SYS-CON MEDIA Authors: Doug Masi, Mat Mathews, PR.com Newswire, David Smith, Tim Crawford

News Feed Item

Non-Invasive Prenatal Testing (NIPT) Market Report

DUBLIN, March 19, 2014 /PRNewswire/ --

Research  and  Markets (http://www.researchandmarkets.com/research/tdmwb8/noninvasive) has announced the addition of the "Non-Invasive Prenatal Testing (NIPT) Market Report" report to their offering.

     (Logo: http://photos.prnewswire.com/prnh/20130307/600769 )

Non-invasive prenatal testing is increasingly being adopted by high risk pregnant women for the screening of common fetal chromosomal aneuploidies such as Down syndrome (trisomy 21), Edwards syndrome (trisomy 18), Patau syndrome (trisomy 13), Turner syndrome (monosomy X) and many others. The non-invasive nature of these tests, their accuracy and safety have been the major reasons behind their popularity among gynecologists and expecting mothers. MaterniT21 was the first NIPT launched in October 2011, by U.S. based Sequenom, Inc. and since then has been leading the market with the largest market share. Sources from Sequenom, Inc. indicate that the company accounts for more than 60% unit share of the high risk pregnancy market in the U.S. Harmony, verifi, Panorama, NIFTY, PrenaTest and BambniTest are other commercially available NIPTs for detecting chromosomal abnormalities.

The exponential growth of the NIPT market is supported by factors such as high incidence rate of babies born with Down syndrome, no risk of miscarriage with NIPT and shifting trend towards child bearing at advanced maternal age (35 years or older). As maternal age is closely associated with the increasing risk of developing a fetus with chromosomal abnormalities, rising maternal age is likely to contribute to the increasing incidence of babies born with chromosomal aneuploidies.

According to Down syndrome education (DSE), in the U.S., the incidence rate for Down syndrome is 1 in every 830 child births (around 4,700 annually), while in Europe the incidence rate is 1 in every 920 babies born (around 9,000 annually), indicating a large potential consumer base for NIPT. Conventional invasive prenatal genetic tests such as amniocentesis and chorionic villus sampling (CVS) are associated with the chance of miscarriage, which is the prime reason for their replacement with new non-invasive prenatal tests. These new NIPTs are based on the analysis of cell-free DNA floating in the maternal plasma and pose no risk of miscarriage.

North America held the largest share in the global NIPT market in terms of revenue in 2012, accounting for 64.5% of the total market revenue. The fact that the major market players are U.S. based along with relatively high awareness levels in the North American region about NIPT are the key factors responsible for the region's leadership position.

In Europe, the market growth largely relies on the increasing penetration of these U.S. based test developers and the expected increase in acceptance of these tests. In the Asia-Pacific market, Japan, Australia, China and India represent the high growth potential markets.

Key  Topics  Covered:

Chapter 1 Preface

Chapter 2 Executive Summary

Chapter 3 Global Non-Invasive Prenatal Testing Market Overview

Chapter 4 Global Non-Invasive Prenatal Testing Market Revenue, by Test, 2012 - 2019 (USD Million)

Chapter 5 Global Non-Invasive Prenatal Testing Market Revenue, by Geography, 2012 - 2019 (USD Million)

Chapter 6 Competitive Landscape

Chapter 7 Recommendations

Chapter 8 Company Profiles

Companies Mentioned:

  • Ariosa Diagnostics, Inc.
  • BGI Health
  • Berry Genomics Co., Ltd
  • LifeCodexx AG
  • Natera, Inc.
  • Sequenom, Inc.
  • Verinata Health, Inc.

For more information visit http://www.researchandmarkets.com/research/tdmwb8/noninvasive

Media  Contact: Laura Wood, +353-1-481-1716, [email protected]

SOURCE Research and Markets

More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.